The first Comprehensive Immune Profiling test designed to help oncologists select the best mono and combination immunotherapy options for their patients.
Peer-reviewed literature demonstrates the need to answer the following critical questions:
- Can the tumor be recognized as “non-self” by the immune system?
- Is the immune response inflamed or suppressed?
- Are the immune cells exhausted or hyper-exhausted?
- Is the tumor immune excluded?
The peer-reviewed literature would support that additional biomarkers influence the response to CPIs:
Only Immune Report Card is designed to provide all the relevant information for clinicians to choose appropriate immunotherapies with an emphasis on checkpoint inhibitors